Prossimo Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-4,520
Closed -$312K 90
2025
Q2
$312K Sell
4,520
-5,327
-54% -$362K 0.25% 98
2025
Q1
$684K Buy
9,847
+224
+2% +$18.5K 0.51% 62
2024
Q4
$828K Buy
9,623
+151
+2% +$16.3K 0.6% 46
2024
Q3
$1.13M Buy
9,472
+142
+2% +$18.9K 0.82% 28
2024
Q2
$1.33M Buy
+9,330
New +$1.24M 1.21% 18
2023
Q3
Sell
-4,520
Closed -$366K 98
2023
Q2
$366K Buy
+4,520
New +$369K 0.35% 90

Other funds holding NVO

Prossimo Advisors's NVO Position: Q3 2025 in Review

Prossimo Advisors sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 4,520 shares — an estimated $312K sold.

Prossimo Advisors first reported a position in NVO in Q2 2023 and held it in 6 quarters. The position peaked at $1.33M in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Prossimo Advisors reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Prossimo Advisors sold 4,520 Novo Nordisk shares in Q3 2025, an estimated $312K.
  • Prossimo Advisors first reported a position in Novo Nordisk in Q2 2023 and held it in 6 quarters.
  • Prossimo Advisors's Novo Nordisk position peaked at $1.33M in Q2 2024.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Prossimo Advisors's 13F filing for Q3 2025, filed 28 Oct 2025.